Terns Pharmaceuticals Inc (NASDAQ:TERN) shares, rose in value on Wednesday, July 09, with the stock price up by 7.95% to the previous day’s close as strong demand from buyers drove the stock to $4.89.
Actively observing the price movement in the last trading, the stock closed the session at $4.53, falling within a range of $4.5996 and $4.92. The value of beta (5-year monthly) was -0.194. Referring to stock’s 52-week performance, its high was $11.40, and the low was $1.87. On the whole, TERN has fluctuated by 32.16% over the past month.
With the market capitalization of Terns Pharmaceuticals Inc currently standing at about $427.08 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TERN’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of TERN currently trading nearly 21.16% and 39.20% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 70.02, while the 7-day volatility ratio is showing 9.76% which for the 30-day chart, stands at 8.75%. Furthermore, Terns Pharmaceuticals Inc (TERN)’s beta value is -0.13.
A comparison of Terns Pharmaceuticals Inc (TERN) with its peers suggests the former has fared considerably weaker in the market. TERN showed an intraday change of 7.95% in last session, and over the past year, it shrunk by -11.73%%.
Data on historical trading for Terns Pharmaceuticals Inc (NASDAQ:TERN) indicates that the trading volumes over the past 10 days have averaged 0.92 and over the past 3 months, they’ve averaged 921.15K. According to company’s latest data on outstanding shares, there are 87.30 million shares outstanding.
Nearly 23.99% of Terns Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 78.80% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.94 million shares as on 2025-06-13, resulting in a short ratio of 7.49. According to the data, the short interest in Terns Pharmaceuticals Inc (TERN) stood at 681.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 5.46 million. The stock has fallen by -28.19% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TERN stock heading into the next quarter.
